Back

Alzheimer's disease induced neurons bearing PSEN1 mutations exhibit reduced excitability

Maksour, S.; Finol-Urdaneta, R. K.; Hulme, A. J.; Cabral-da-Silva, M. C.; Targa Dias Anastacio, H.; Balez, R.; Berg, T.; Turner, C.; Sanz Munoz, S.; Engel, M.; Kalajdzic, P.; Lisowski, L.; Sidhu, K.; Sachdev, P. S.; Dottori, M.; Ooi, L.

2024-03-23 cell biology
10.1101/2024.03.22.586207 bioRxiv
Show abstract

Alzheimers disease (AD) is a devastating neurodegenerative condition that affects memory and cognition, characterized by neuronal loss and currently lacking a cure. Mutations in PSEN1 (Presenilin 1) are among the most common causes of early-onset familial AD (fAD). While changes in neuronal excitability are believed to be early indicators of AD progression, the link between PSEN1 mutations and neuronal excitability remains to be fully elucidated. This study examined induced pluripotent stem cell (iPSC)-derived NGN2 induced neurons (iNs) from fAD patients with PSEN1 mutations S290C or A246E, alongside CRISPR-corrected isogenic cell lines, to investigate early changes in excitability. Electrophysiological profiling revealed reduced excitability in both PSEN1 mutant iNs compared to their isogenic controls. Neurons bearing S290C and A246E mutations exhibited divergent passive membrane properties compared to isogenic controls, suggesting distinct effects of PSEN1 mutations on neuronal excitability. Additionally, both PSEN1 backgrounds exhibited higher current density of voltage-gated potassium (Kv) channels relative to their isogenic iNs, while displaying comparable voltage-gated sodium (Nav) channel current density. This suggests that the Nav/Kv imbalance contributes to impaired neuronal firing in fAD iNs. Deciphering these early cellular and molecular changes in AD is crucial for understanding the disease pathogenesis.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Neurobiology of Disease
134 papers in training set
Top 0.1%
43.3%
2
Acta Neuropathologica Communications
81 papers in training set
Top 0.2%
3.9%
3
Alzheimer's & Dementia
143 papers in training set
Top 1%
3.9%
50% of probability mass above
4
Scientific Reports
3102 papers in training set
Top 42%
3.0%
5
International Journal of Molecular Sciences
453 papers in training set
Top 4%
2.6%
6
PLOS ONE
4510 papers in training set
Top 47%
2.3%
7
GeroScience
97 papers in training set
Top 0.8%
2.1%
8
Advanced Science
249 papers in training set
Top 9%
2.1%
9
Molecular Psychiatry
242 papers in training set
Top 2%
1.8%
10
iScience
1063 papers in training set
Top 13%
1.8%
11
ACS Chemical Neuroscience
60 papers in training set
Top 1%
1.6%
12
Neurobiology of Aging
95 papers in training set
Top 2%
1.3%
13
Frontiers in Aging Neuroscience
67 papers in training set
Top 2%
1.2%
14
eLife
5422 papers in training set
Top 51%
1.0%
15
Alzheimer's Research & Therapy
52 papers in training set
Top 1%
1.0%
16
Cells
232 papers in training set
Top 5%
0.9%
17
Journal of Alzheimer’s Disease
39 papers in training set
Top 1.0%
0.9%
18
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 8%
0.8%
19
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.5%
0.8%
20
Cell Reports
1338 papers in training set
Top 32%
0.8%
21
The FASEB Journal
175 papers in training set
Top 3%
0.8%
22
Frontiers in Aging
10 papers in training set
Top 0.4%
0.8%
23
Molecular Neurodegeneration
49 papers in training set
Top 1.0%
0.7%
24
International Journal of Biological Macromolecules
65 papers in training set
Top 4%
0.7%
25
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.7%
26
Nature Communications
4913 papers in training set
Top 66%
0.5%
27
Acta Neuropathologica
51 papers in training set
Top 1%
0.5%
28
Brain, Behavior, and Immunity
105 papers in training set
Top 3%
0.5%
29
Communications Biology
886 papers in training set
Top 31%
0.5%
30
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.4%
0.5%